Prescribing information

 

This video explains the correct injection technique for patients and caregivers administering ILARIS.

Do not share links to this website or screenshots with patients as this website is intended for healthcare professionals only.

If you do wish to share this video with patients, please share this link: https://health.novartis.co.uk/public/medicines/rare-diseases/ilaris/patient-resources/administration-video

 

Indications1

ILARIS is indicated for the treatment of the following autoinflammatory periodic fever syndromes in adults, adolescents and children aged 2 years and older:

  • Cryopyrin-associated periodic syndromes (CAPS), including:
    • Muckle-Wells syndrome (MWS)
    • Neonatal-onset multisystem inflammatory disease (NOMID)/chronic infantile neurological, cutaneous, articular syndrome (CINCA)
    • Severe forms of familial cold autoinflammatory syndrome (FCAS)/familial cold urticaria (FCU) presenting with signs and symptoms beyond cold-induced urticarial skin rash.
  • Tumour necrosis factor (TNF) receptor-associated periodic syndrome (TRAPS).
  • Hyperimmunoglobulin D syndrome (HIDS)/mevalonate kinase deficiency (MKD).
  • Familial Mediterranean fever (FMF). ILARIS should be given in combination with colchicine, if appropriate.

 

HCP, healthcare professional.

Reference

  1. ILARIS® (canakinumab) Summary of Product Characteristics.
ILA20-C008e September 2020.
×

Ask Speakers

×

Medical Information Request

Adverse events should be reported. Reporting forms and information can be found at yellowcard.mhra.gov.uk. Adverse events should also be reported to Novartis via [email protected] or online through the pharmacovigilance intake (PVI) tool at http://www.report.novartis.com/
If you have a question about the product, please contact Medical Information on 01276 698370 or by email at [email protected]